5th Pharma Risk & Compliance Virtual Summit 2021

Lexplosion Webinar dated 15-December-2021 | 5th Pharma Risk & Compliance Virtual Summit 2021

Pharmaceutical Industry is heavily regulated in India. While the professionals in the pharmaceutical industry are well versed with the compliance requirement, it is essential to get a proper guidance on measuring risk, laying down a process and establishing an effective control to mitigate risk on non-compliance. Handling these complexities successfully, demands the use of technology-driven solutions.

In this summit, we broadly spoke about:

  1. The Future of Pharma Regulations in 2022
  2. Ways to identify Risks
  3. Path towards mitigation through technology
  4. Regulation & Compliance with government policies in a pharmaceutical

The key aspects discussed by the panel are: Best ways to integrate regulatory intelligence

  • The next gen compliance tool to maintain the regulations
  • Designing and Implementing interventions to minimize the risk effectively
  • Understand the method of advanced monitoring
  • Access ways to weigh cost and benefit of compliance

Komrisk clients from Apotex Research Pvt. Ltd., Ajanta Pharma Limited and Ferring Pharmaceutical Private Limited also shared their experiences about how managing compliances and mitigating risks from non-compliance is not a cumbersome process after using Komrisk. Mr. Gaurang Shah-VP, Legal & Corporate Affairs & Company Secretary at Ajanta Pharma Limited, Mr. Indrajyoti Bose-CFO & Compliance Officer at Apotex Research Pvt. Ltd., and Mr. Sudip Suryawanshi-Associate Director, Finance & IT at Ferring Pharmaceutical Private Limited explained the user-friendliness of Komrisk and how important it is to keep a systematic compliance process in place within an organization. Watch the video now, to get key insights from top Pharmaceutical Industry leaders on how they are mitigating the risks of non-compliance effectively.

Subscribe for Upcoming Webinars

Webinar Registration

  • This field is for validation purposes and should be left unchanged.